NTC014: Revolutionary eye drops against bacterial conjunctivitis!
NTC014: Revolutionary eye drops against bacterial conjunctivitis!
Laimgrubengasse 10, 1060 Wien, Österreich - The American and Asian pharmaceutical world is about to revolution in the treatment of bacterial conjunctivitis. NTC, a pharmaceutical company with headquarters in Italy specializing in research, has published groundbreaking results of the phase-II mirakle study. This multicenter study examines the new drug NTC014, a combination of a quinolon antibiotic and a non-steroidal anti-rheumatic (NSAID) in the form of eye drops. According to the NTC, the results match the idea of using fewer antibiotics, which means that the treatment costs and the risk of antibiotic resistance can be reduced. "These preliminary results confirm that NTC014 comes into question as a new treatment for bacterial conjunctivitis," explains Alessandro Colombo, Chief Scientific Officer at NTC, and highlights the great potential of the drug.
In addition to the positive study results, NTC has completed an exclusive license agreement with the ZHAoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, which enables ZHAOKE to drive NTC014 in China and several other Asian markets. This strategy aims to offer doctors an innovative and effective treatment option for moderate bacterial conjunctivitis. "We are proud of the partnership with Zhaoke, an innovative company," said Riccardo Carbucicchio, CEO from NTC. "NTC014 will make first -class treatment available for millions of patients," he added, while emphasizing the importance of NTC014 in combating bacterial infections.innovative treatment in sight
The product, which is a first oral solution, combines a highly effective antibiotic with an NSAID that controls the symptoms and signs of inflammation. This innovative solution will not only increase the efficiency of treatment, but also support NTC's plans to reduce the number of medication required and the duration of treatment. Dr. Benjamin Li, CEO von Zhaoke, was enthusiastic about the cooperation: "This partnership with NTC perfectly corresponds to our mission to bring innovative therapies to China and the Asian markets." The development of NTC014 could thus lead to a significant improvement in medical care in ophthalmology, as NTC also emphasized in its press release. For more information about NTC and your products, visit the website of ntc pharma .
| Details | |
|---|---|
| Ort | Laimgrubengasse 10, 1060 Wien, Österreich |
| Quellen | |